F12. CLINICALLY ACTIONABLE PHARMACOGENOMIC LANDSCAPE OF PSYCHOTROPICS IN QATAR
Velayutham D, Bastaki K, Irfan A, Abuhaliqa M, Ghuloum S, Azeem M, Pirmohamed M, Jithesh P. F12. CLINICALLY ACTIONABLE PHARMACOGENOMIC LANDSCAPE OF PSYCHOTROPICS IN QATAR. European Neuropsychopharmacology 2024, 87: 211. DOI: 10.1016/j.euroneuro.2024.08.423.Peer-Reviewed Original ResearchClinical Pharmacogenetics Implementation ConsortiumDutch Pharmacogenetics Working GroupGenetic variationClinical Pharmacogenetics Implementation Consortium recommendationsMetabolic phenotypeWhole-genome sequencing dataImplementing PGx testingGenome sequence dataIntegration of pharmacogenomicsPharmacogenetics Working GroupAnalysis of haplotypesQatari populationPGx testingSequence dataImplementation ConsortiumUltrarapid metabolizersPharmacogenetic testingPharmacokinetic genesGenetic variantsCase of antipsychoticsPsychotropic medication responseResponse to antidepressantsResponse phenotypesCase of haloperidolChoice of therapy